Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of ABT-888 in Combination With Oxaliplatin and Capecitabine in Advanced Solid Tumors

NCT01233505 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT01233505
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01233505 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of ABT-888 in Combination With Oxaliplatin and Capecitabine in Advanced Solid Tumors
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1
Overall status
Terminated
Start date
October 31, 2010
Completion date
Not reported
Enrollment
16 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adenocarcinoma of the pancreas, adenocarcinoma of the stomach, brca1 mutation carrier, brca2 mutation carrier, ovarian mucinous cystadenocarcinoma, recurrent breast cancer, recurrent colon cancer, recurrent gastric cancer, recurrent ovarian epithelial cancer, recurrent ovarian germ cell tumor, recurrent pancreatic cancer, recurrent rectal cancer, stage ia breast cancer, stage ib breast cancer, stage ii breast cancer, stage iiia breast cancer, stage iiib breast cancer, stage iiic breast cancer, stage iv breast cancer, stage iv colon cancer, stage iv gastric cancer, stage iv ovarian epithelial cancer, stage iv ovarian germ cell tumor, stage iv pancreatic cancer, stage iv rectal cancer, unspecified adult solid tumor, protocol specific